Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / ASCO 2026 Oncology Data Presentations
Tech oncology data presentation

ASCO 2026 Oncology Data Presentations

Analysis based on 26 articles · First reported May 25, 2026 · Last updated Jun 08, 2026

Sentiment
60
Attention
8
Articles
26
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The presentations of new oncology data by Menarini Group, Jiangsu Hengrui, Kura Oncology, and Akeso at the ASCO Annual Meeting are expected to positively impact the pharmaceutical and biotechnology sectors. Positive clinical trial results, especially for innovative therapies like darlifarnib and various combination treatments, can lead to increased investor confidence and potential future revenue streams for the involved companies. The advancements in cancer treatment options could also benefit the broader healthcare market by improving patient outcomes.

pharmaceuticals biotechnology healthcare
Event Summary

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 29 to June 2, served as a crucial platform for major pharmaceutical and biotechnology companies to present significant advancements in cancer research and clinical development. Menarini Group, through its subsidiary AnBogen Therapeutics, announced new data on elacestrant and tagraxofusp, highlighting their potential in various cancer treatments. Jiangsu Hengrui showcased over 90 studies, emphasizing its broad oncology pipeline and innovative therapies across gastrointestinal, breast, lung, urological, and gynecological cancers, as well as supportive care. Kura Oncology presented new clinical and translational data for darlifarnib, positioning it as a foundational combination platform for KRAS-mutant cancers and outlining its expanded development strategy. Akeso also featured prominently, presenting over 40 clinical studies, including a Late-Breaking Abstract for its bispecific antibodies cadonilimab and ivonescimab. These presentations underscore ongoing investment in oncology innovation and the potential for new treatment options for patients.

Key Actions
100 Menarini Group announced new data
100 Akeso presented Phase III results Ivonescimab
95 Jiangsu Hengrui presented studies American Society of Clinical Oncology
90 AnBogen Therapeutics announced new data
90 Kura Oncology highlighted data American Society of Clinical Oncology
85 Akeso presented clinical data Cadonilimab
85 Kura Oncology highlighted data
80 Akeso announced presentations American Society of Clinical Oncology
70 Karyopharm Therapeutics presented data
70 Karyopharm Therapeutics presented data American Society of Clinical Oncology
70 Akeso presented data Ligufalimab
70 Kura Oncology hosted investor event
60 Zhenzhen Liu led study
60 Jin Li co-led study
60 Ying Yuan co-led study
+ 8 more actions View on Dashboard
Entities Involved
ngo
American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) Annual Meeting is the key venue where the new oncology data from various pharmaceutical companies, including Menarini Group, Jiangsu Hengrui, Kura Oncology, and Akeso, were presented.
Importance 100 Sentiment 0
stock
Jiangsu Hengrui
Jiangsu Hengrui presented over 90 studies at the 2026 ASCO Annual Meeting, showcasing its extensive oncology pipeline and innovative therapies across various cancer types, demonstrating its continued investment in drug development.
Importance 95 Sentiment 70
priv
Menarini Group
The Menarini Group announced new data related to elacestrant and tagraxofusp at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its dedication to oncology research and development.
Importance 90 Sentiment 70
stock
Kura Oncology
Kura Oncology highlighted new clinical and translational data for darlifarnib at the 2026 ASCO Annual Meeting, supporting its potential as a foundational combination platform for KRAS-mutant cancers and outlining its development strategy.
Importance 90 Sentiment 75
oth
Ivonescimab
Ivonescimab is a core first-in-class bispecific antibody developed by Akeso, with Phase III overall survival results from the HARMONi-6 study being a pivotal highlight at ASCO 2026. Its positive data in various cancers could lead to significant market impact.
Importance 90 Sentiment 70
stock
Akeso
Akeso announced that over 40 clinical studies of its oncology portfolio, including data on cadonilimab and ivonescimab, were presented at the 2026 ASCO Annual Meeting, with one Late-Breaking Abstract selected for a Plenary Session.
Importance 80 Sentiment 65
oth
Cadonilimab
Cadonilimab is another core first-in-class bispecific antibody from Akeso's portfolio, with regimens being presented for various tumor types at ASCO 2026, indicating its potential clinical benefits.
Importance 80 Sentiment 65
priv
AnBogen Therapeutics
AnBogen Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced new data related to elacestrant and tagraxofusp at the 2026 ASCO Annual Meeting, and its partner Karyopharm Therapeutics presented data on selinexor.
Importance 70 Sentiment 65
stock
Karyopharm Therapeutics
Karyopharm Therapeutics, a partner of AnBogen Therapeutics, presented late-breaking oral presentation data from the phase 3 SENTRY trial of selinexor in myelofibrosis at the ASCO Annual Meeting.
Importance 70 Sentiment 60
per
Naveen Pemmaraju
Naveen Pemmaraju, MD, Professor at The University of Texas MD Anderson Cancer Center, presented new phase 2 tagraxofusp combination data in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Importance 50 Sentiment 60
oth
Ligufalimab
Ligufalimab is a novel therapeutic antibody from Akeso, a next-generation CD47 monoclonal antibody, also featured in presentations at ASCO 2026.
Importance 50 Sentiment 60
per
Elcin Barker Ergun
Elcin Barker Ergun, CEO of the Menarini Group, emphasized the company's dedication to tackling difficult-to-treat cancers and accelerating innovation in targeted therapies.
Importance 40 Sentiment 60
per
Troy E. Wilson
Troy E. Wilson, President and CEO of Kura Oncology, reinforced the belief that darlifarnib has the potential to become a foundational combination backbone for molecularly defined cancers.
Importance 40 Sentiment 60
per
Mollie Leoni
Mollie Leoni, Chief Medical Officer of Kura Oncology, stated that darlifarnib may have broad applicability across expanding classes of therapies, creating opportunities for improved patient outcomes and future collaborations.
Importance 40 Sentiment 60
per
Shun Lu
Professor Shun Lu from Shanghai Chest Hospital is the presenter for the Plenary Session on ivonescimab's HARMONi-6 study results.
Importance 40 Sentiment 0
+ 24 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.